Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

nd fractured a hip; death was attributed to renal failure and pulmonary sepsis.

"I am thrilled by the data from this Phase 2 study of VP20621, which confirm the therapeutic potential of non-toxigenic C. difficile," commented Dale Gerding , MD, Professor of Medicine at Loyola University Chicago Stritch School of Medicine and research physician at the Hines VA Hospital. "For the first time, we have been able to mimic the protective effect we have inferred from observing natural colonization of patients with non-toxigenic strains of C. difficile. As a clinician on the front lines of CDI research, I find these data to be extremely promising and suggestive of a novel approach to prevention of not only disease recurrence, but primary CDI as well."

Next steps
ViroPharma will complete the evaluation of these Phase 2 data which will help determine a future development pathway. The company reminds its investors that VP20621 was flagged as a non core asset at its September investor event. With these compelling Phase 2 clinical results, we will seek a partner to complete the development and commercialization of the asset.

About VP20621
Antibiotics including those used to treat acute C. difficile infection (CDI) disrupt the normal gastrointestinal flora which renders individuals susceptible to C. difficile colonization. Orally-dosed liquid VP20621 utilizes non-toxigenic spore-based technology as a potential means of recolonization and protection. The goal of VP20621 dosing following antibiotic exposure is to colonize with this non-toxigenic strain of C. difficile and to prevent colonization by toxigenic strains, thereby preventing disease. VP20621 may have therapeutic utility in the prevention of recurrence following treatment of acute CDI and in the primary prevention of CDI. ViroPharma acquired VP20621 in 2006, through a licensing agreement with Dr.
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... Dec 12, 2014 Mindray Medical International Limited ... manufacturer and marketer of medical devices worldwide, today announced ... shareholders held in Hong Kong ... Mindray shareholders voted to re-elect incumbent directors Li Xiting ... Mindray,s shareholders did not re-elect Peter Wan ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo ... Racing Teams (CGRT), today announced a multi-year extension of their ... of the No. 83 Novo Nordisk Chip Ganassi Racing entry, ... Series. Kimball, 29, from Camarillo, ... with diabetes in the history of INDYCAR to win a ...
(Date:12/13/2014)... DUBLIN , Dec. 11, 2014 Research ... announced the addition of the "China Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... of chemical drug preparation and active pharmaceutical ingredient ... preparation industry is generally higher than that of ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... PRINCETON, N.J. , June 14 Covance Inc. (NYSE: ... Company,s 30th Annual Growth Stock Conference on Wednesday, June 16, 2010 ... the presentation at www.covance.com .  In order to register and download any ... , , ...
... June 14 MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ... Cheshire, England to manage its planned Phase IIb clinical trial ... candidate for treatment of primary multiple sclerosis-related fatigue (PMSF). , ... In an earlier Phase IIa study, MCT-125 ...
Cached Medicine Technology:MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 2MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 3MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... to lose weight might consider heading to the cardio ... out this month. // ,Both those who ... of weight, according to findings from an NIH-funded study ... while exercisers maintained their strength and muscle mass and ...
... produced a vaccine that activates the immune systems in ... ,During a clinical trial of 67 patients, researchers ... vaccines were injected pre and post surgery of the ... nearly 70 percent of patients. The November 15 issue ...
... drinks works as well as some sports drinks like Gatorade. ... and conducted by Indiana University // suggested found that ... 50% longer than those drinking a carbohydrate drink, an effect ... ,The story was picked up as mainstream news in ...
... memory during and after menopause, a change thought to be ... during that time. // ,Now, research from the ... help women retain certain memory functions. In a study in ... Metabolism, they report that a group of postmenopausal women showed ...
... hearing damage from acoustic shock, say health experts. // , ... functioning of the ear or of the nervous system, which ... earphone by a sudden sharp rise in the acoustic pressure ... a bleep or any unexpected noise. Two thirds of call ...
... identified by scientists from the Wistar Institute in Philadelphia and ... repression of the p53 protein // which is the most ... ,The new molecular pathway described in the study suggests ... many types of cancer. A report on the team's findings ...
Cached Medicine News:Health News:New Study Weighs Benefits of Exercise, Diets 2Health News:A novel vaccine proves a shot in the arm for colorectal cancer patients 2Health News:Hormone Therapy May Improve the Trip Down Memory Lane 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 3
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Chrome plated brass. The Laryngoscope handle that ... secret is the o-rings which create a ... you to keep the batteries in when ... a high quality standard/conventional chrome-plated brass handle ...
... with blade. Rusch offers a reliable tradition ... The designs of these blades have been ... the world over to minimize maintenance requirements. ... the finest surgical grade stainless steel to ...
... laryngoscope blades are designed with the clinician ... bundle can be removed to simplify cleaning ... areas. Our unique snap-on mechanism eliminates screws ... blades are interchangeable with other green coded ...
Medicine Products: